NCT05000294
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1|Phase 2
Drug Category: Immunotherapy, Therapeutic Antibody, Tyrosine-Kinase Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years to 99 Years (Adult, Older Adult)
Location of Metastases: 
Additional Notes: HER2+ patients must have received at least 3 lines of therapy for disease progression that includes: Herceptin/trastuzumab, Perjeta/pertuzumab, & Kadcyla/ado-trastuzumab emtansine; Patients without HER2+ breast cancer must have a neuroendocrine tumor
Exclusions: Patients with known tumors that express MSI-H (microsatellite high) or mismatch repair (MMR) deficiency; Patients with prior use of checkpoint inhibitor immunotherapy or tyrosine kinase inhibitor (e.g. Tukysa/tucatinib, Nerlynx/neratinib); Patients with active untreated brain metastasis – see trial for details; Patients with a history of leptomeningeal disease
https://ClinicalTrials.gov/show/NCT05000294